COVID-19: Viral Effect on Clinical Trials
The onset of the COVID-19 virus has simultaneously affected each country and each industry and is challenging us all to seek alternative and innovative ways to continue business-as-usual activities.
Clinical trials remain an essential component of Oncology patient care and each site is proactively addressing how to support trial activity under these new and unprecedented conditions.
- Sites have been collaborating with each other to determine how to respond to:
- Clinical Trial Operational Considerations that includes options for Sponsor remote monitoring
- Risk Reduction Initiatives for patients that include Telehealth and Teletrial options for patient visits
- Workforce Considerations to support ongoing trials and the best use of shared resourcing
Sites are also assessing their resources to support the implementation and ongoing management of COVID-19 clinical trials.